title: Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy.
abstract: OBJECTIVE
  The Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial is a randomized comparison of combined antiplatelet with anticoagulant therapy after coronary Palmaz-Schatz stent placement. The objective of this study was to compare early and late clinical and angiographic outcome in a subgroup of patients with stent placement for acute myocardial infarction.
  
  
  BACKGROUND
  Stenting has become a treatment option for acute myocardial infarction, but it is not known which antithrombotic regimen is more adequate after stent implantation.
  
  
  METHODS
  One hundred twenty-three patients with successful stenting after acute myocardial infarction were randomized to receive aspirin plus ticlopidine (n = 61) or intense anticoagulant therapy (n = 62). Six-month repeat angiography was performed in 101 (86.3%) eligible patients.
  
  
  RESULTS
  During the first 30 days after stenting, patients with antiplatelet therapy had a significantly lower clinical event rate (3.3% vs. 21.0%, p = 0.005) and stent vessel occlusion rate (0% vs. 9.7%, p = 0.03) and a trend to fewer cardiac events (1.6% vs. 9.7%, p = 0.12). After 6 months, the survival rate free of recurrent myocardial infarction was higher in patients with antiplatelet therapy (100% vs. 90.3%, p = 0.03), and the rate of stent vessel occlusion was lower (1.6% vs. 14.5%, p = 0.02). Both groups had comparable restenosis rates (26.5% vs. 26.9%, p = 0.87).
  
  
  CONCLUSIONS
  This study demonstrates that combined antiplatelet therapy after stent placement in patients with acute myocardial infarction is associated with an overall better clinical and angiographic outcome than anticoagulant therapy.
authors.affiliation: 1. Medizinische Klinik, Klinikum rechts der Isar, Munich, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Schömig
authors.forename: F J
authors.initials: FJ
authors.lastname: Neumann
authors.forename: H
authors.initials: H
authors.lastname: Walter
authors.forename: H
authors.initials: H
authors.lastname: Schühlen
authors.forename: M
authors.initials: M
authors.lastname: Hadamitzky
authors.forename: E M
authors.initials: EM
authors.lastname: Zitzmann-Roth
authors.forename: J
authors.initials: J
authors.lastname: Dirschinger
authors.forename: J
authors.initials: J
authors.lastname: Hausleiter
authors.forename: R
authors.initials: R
authors.lastname: Blasini
authors.forename: C
authors.initials: C
authors.lastname: Schmitt
authors.forename: E
authors.initials: E
authors.lastname: Alt
authors.forename: A
authors.initials: A
authors.lastname: Kastrati
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000008:administration & dosage* / Q000627:therapeutic use; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000628:therapy*; D010644:Phenprocoumon / Q000008:administration & dosage / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012008:Recurrence; D015607:Stents; D015996:Survival Rate; D013988:Ticlopidine / Q000008:administration & dosage* / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D013988:Ticlopidine; D010644:Phenprocoumon; D001241:Aspirin